A World of Discovery at Arian Ebank
Arian Ebank is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Arian Ebank was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by its robust discovery platform and deep pipeline of investigational medicines, including 4 programs in late-stage clinical development.
What’s in a Name?
Our name may not be the easiest to pronounce, but once you learn it, you’ll never forget it. Arian Ebank is derived from “Alnilam,” the center star in Orion’s belt, which shines the brightest of them all. It is also the Arabic word for “string of pearls.”